# Complete Summary

#### TITLE

End stage renal disease (ESRD): percentage of adult hemodialysis (HD) patients with anemia or if prescribed Epoetin with at least one documented transferrin saturation and serum ferritin concentration result every three months.

# SOURCE(S)

Centers for Medicare & Medicaid Services. 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures project. Baltimore (MD): Centers for Medicare & Medicaid Services, Center for Beneficiary Choices; 2004 Dec. 100 p.

#### Measure Domain

## PRIMARY MEASURE DOMAIN

# **Process**

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

# SECONDARY MEASURE DOMAIN

Does not apply to this measure

#### **Brief Abstract**

# **DESCRIPTION**

This measure is used to assess the percentage of adult hemodialysis (HD) patients with anemia or if prescribed Epoetin with at least one documented transferrin saturation and serum ferritin concentration result every three months.

# **RATIONALE**

The ESRD Clinical Performance Measures (CPM) Project is a national effort led by the Centers for Medicare & Medicaid Services (CMS), formerly the Health Care Financing Administration (HCFA), and its eighteen ESRD Networks to assist dialysis providers to improve patient care and outcomes.

The purpose of the ESRD CPM Project is to provide comparative data to ESRD caregivers to assist them in assessing and improving the care provided to dialysis patients.

While significant improvements in care have occurred, the opportunities to improve care for dialysis patients in the U.S. in the areas of adequacy of dialysis, vascular access, and anemia management continue.

#### PRIMARY CLINICAL COMPONENT

End stage renal disease (ESRD); hemodialysis (HD); anemia; hemoglobin (Hgb); Epoetin; transferrin saturation; serum ferritin

#### DENOMINATOR DESCRIPTION

All adult (greater than or equal to 18 years old) hemodialysis (HD) patients included in the sample for analysis, if first monthly hemoglobin (Hgb) is less than 11 g/dL (110 g/L) for at least one of the study months\* or if prescribed Epoetin at any time during the study period regardless of Hgb

\*The most recent data collected for the End Stage Renal Disease (ESRD) Clinical Performance Measures (CPM) Project were for the 3 month time period (October - December 2003) for the in-center HD patients. However, facilities implementing this measure may choose any time period.

#### NUMERATOR DESCRIPTION

Number of hemodialysis (HD) patients in the denominator with at least one documented transferrin saturation and serum ferritin concentration result every three months

#### Evidence Supporting the Measure

## EVIDENCE SUPPORTING THE CRITERION OF QUALITY

 A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

# Evidence Supporting Need for the Measure

## NEED FOR THE MEASURE

Use of this measure to improve performance

#### EVIDENCE SUPPORTING NEED FOR THE MEASURE

Centers for Medicare & Medicaid Services. 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures project. Baltimore (MD): Centers for Medicare & Medicaid Services, Center for Beneficiary Choices; 2004 Dec. 100 p.

#### State of Use of the Measure

## STATE OF USE

Current routine use

**CURRENT USE** 

External oversight/Medicare Internal quality improvement National reporting

# Application of Measure in its Current Use

## CARE SETTING

**Ambulatory Care** 

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Single Health Care Delivery Organizations

TARGET POPULATION AGE

Age greater than or equal to 18 years

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

#### Characteristics of the Primary Clinical Component

# INCIDENCE/PREVALENCE

The incidence of treated end stage renal disease (ESRD) in the United States is 333 per million population. As of December 31, 2003, there were 310,095 patients receiving dialysis therapy in the United States.

EVIDENCE FOR INCIDENCE/PREVALENCE

Centers for Medicare & Medicaid Services. 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures project. Baltimore (MD): Centers for Medicare & Medicaid Services, Center for Beneficiary Choices; 2004 Dec. 100 p.

#### ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

**BURDEN OF ILLNESS** 

Unspecified

**UTILIZATION** 

Unspecified

**COSTS** 

Unspecified

# Institute of Medicine National Healthcare Quality Report Categories

**IOM CARE NEED** 

Living with Illness

IOM DOMAIN

Effectiveness

#### Data Collection for the Measure

CASE FINDING

Users of care only

## DESCRIPTION OF CASE FINDING

All adult (greater than or equal to 18 years old) hemodialysis (HD) patients included in the sample for analysis, if first monthly hemoglobin (Hgb) is less than 11 g/dL (110 g/L) for at least one of the study months\* or if prescribed Epoetin at any time during the study period regardless of Hgb

# DENOMINATOR SAMPLING FRAME

<sup>\*</sup>The most recent data collected for the End Stage Renal Disease (ESRD) Clinical Performance Measures (CPM) Project were for the 3 month time period (October - December 2003) for the in-center HD patients. However, facilities implementing this measure may choose any time period.

# Patients associated with provider

## DENOMINATOR INCLUSIONS/EXCLUSIONS

#### Inclusions

All adult (greater than or equal to 18 years old) hemodialysis (HD) patients included in the sample for analysis, if first monthly hemoglobin (Hgb) is less than 11 g/dL (110 g/L) for at least one of the study months\* or if prescribed Epoetin at any time during the study period regardless of Hgb

\*The most recent data collected for the End Stage Renal Disease (ESRD) Clinical Performance Measures (CPM) Project were for the 3 month time period (October - December 2003) for the in-center HD patients. However, facilities implementing this measure may choose any time period.

Exclusions Unspecified

#### RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

# DENOMINATOR (INDEX) EVENT

Clinical Condition
Therapeutic Intervention

#### DENOMINATOR TIME WINDOW

Time window precedes index event

## NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Number of hemodialysis (HD) patients in the denominator with at least one documented transferrin saturation and serum ferritin concentration result every three months

Exclusions Unspecified

# MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## NUMERATOR TIME WINDOW

Fixed time period

**DATA SOURCE** 

Medical record

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

# Computation of the Measure

**SCORING** 

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

External comparison at a point in time External comparison of time trends Internal time comparison

#### Evaluation of Measure Properties

# EXTENT OF MEASURE TESTING

Unspecified

#### Identifying Information

ORIGINAL TITLE

Anemia management CPM IIa: assessment of iron stores among anemic patients or patients prescribed Epoetin.

MEASURE COLLECTION

**ESRD Clinical Performance Measures** 

#### MEASURE SET NAME

## Anemia Management

## **DEVELOPER**

Centers for Medicare & Medicaid Services

#### **ADAPTATION**

Measure was not adapted from another source.

#### RELEASE DATE

1999 Dec

#### **MEASURE STATUS**

This is the current release of the measure.

# SOURCE(S)

Centers for Medicare & Medicaid Services. 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures project. Baltimore (MD): Centers for Medicare & Medicaid Services, Center for Beneficiary Choices; 2004 Dec. 100 p.

# MEASURE AVAILABILITY

The individual measure, "Anemia Management CPM IIa: Assessment of Iron Stores among Anemic Patients or Patients Prescribed Epoetin," is published in "2004 Annual Report, End Stage Renal Disease Clinical Performance Measures Project." This document is available in Portable Document Format (PDF) from the Centers for Medicare and Medicaid Services (CMS) Web site.

For more information, refer to the CMS Web site at, www.cms.hhs.gov.

# NQMC STATUS

This NQMC summary was completed by ECRI on July 15, 2005. The information was verified by the measure developer on August 9, 2005.

#### COPYRIGHT STATEMENT

No copyright restrictions apply.

© 2006 National Quality Measures Clearinghouse

Date Modified: 9/25/2006



